Helicobacter pylori and benign upper digestive disease

Best Practice and Research in Clinical Gastroenterology

Volumn 21, Issue 2, 2007, Pages 261-279

  Lai, Larry H ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

benign; Helicobacter pylori; upper gastrointestinal disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

ACHLORHYDRIA; ARTICLE; BACTERIAL TRANSMISSION; BLEEDING; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC RISK; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH ULCER; SYSTEMATIC REVIEW; ULCER; UPPER GASTROINTESTINAL TRACT;

EID: 33947193628     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.10.002     Document Type: Article

References (129)

1. Marshall B.J., and Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (1984) 1311-1315
2. Graham D.Y., Malaty H.M., Evans D.G., et al. Epidemiology of H. pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100 (1991) 1495-1501
3. Webb P.M., Knight T., Greaves S., et al. Relation between infection with H. pylori and living conditions in childhood: evidence for person to person transmission in early life. BMJ 308 (1994) 750-753
4. Pounder R.E., and Ng D. The prevalence of H. pylori infection in different countries. Aliment Pharmacol Ther 9 supplement 2 (1995) 33-39
5. Megraud F. Transmission of H. pylori: faecal-oral versus oral-oral route. Aliment Pharmacol Ther 9 supplement 2 (1995) 85-91
6. Passaro D.J., Taylor D.N., Meza R., et al. Acute H. pylori infection is followed by an increase in diarrheal disease among Peruvian children. Pediatrics 108 (2001) E87
7. Passaro D.J., Taylor D.N., Gilman R.H., et al. Growth slowing after acute H. pylori infection is age-dependent. J Pediatr Gastroenterol Nutr 35 (2002) 522-526
8. Marshall B.J., Armstrong J.A., McGechie D.B., et al. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust 142 (1985) 436-439
9. Morris A., and Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 (1987) 192-199
10. Graham D.Y., Alpert L.C., Smith J.L., et al. Iatrogenic Campylobacter pyloric infection is a cause of epidemic achlorhydria. Am J Gastroenterol 83 (1988) 974-980
11. Harford W.V., Barnett C., Lee E., et al. Acute gastritis with hypochlorhydria: report of 35 cases with long-term follow-up. Gut 47 (2000) 467-472
12. Sobala G.M., Crabtree J.E., Dixon M.F., et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 32 (1991) 1415-1418
13. Ramsey E.J., Carey K.V., Peterson W.L., et al. Epidemic gastritis with hypochlorhydria. Gastroenterology 76 (1979) 1449-1457
14. Jablonowski H., Hengels K.J., Kraemer N., et al. Effects of Helicobacter pylori on histamine and carbachol stimulated acid secretion by human parietal cells. Gut 35 (1994) 755-757
15. Guarino A., Bisceglia M., Canani R.B., et al. Enterotoxic effect of the vacuolating toxin produced by Helicobacter pylori in Caco-2 cells. J Infect Dis 178 (1998) 1373-1378
16. El-Olmar E.M., Oien K., El-Nujumi A., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997) 15-24
17. Faber K. Chronic gastritis: its relation to achylia and ulcer. Lancet 2 (1927) 902-907
18. Chen L., and Crawford J.M. The gastrointestinal tract. In: Kumar V., Abbas A.K., and Fausto N. (Eds). Robbins and Cotran Pathologic Basis of Disease. 7th ed. (2005), Elsevier Saunders, Philadelphia 810-812
19. Fan X., Gunasena H., Cheng Z., et al. Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol 165 (2000) 1918-1924
20. Yamaoka Y., Kita M., Kodama T., et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 110 (1996) 1744-1752
21. Negrini R., Savio A., and Appelmelk B.J. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 2 supplement 1 (1997) S13-S16
22. Zhang Q.B., Nakashabendi I.M., Mokhashi M.S., et al. Association of cytotoxin production and neutrophil activation by strains of Helicobacter pylori isolated from patients with peptic ulceration and chronic gastritis. Gut 38 (1996) 841-845
23. Rudi J., Kuck D., Strand S., et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest 102 (1998) 1506-1514
24. Atherton J.C. CagA: a role at last. Gut 47 (2000) 330-331
25. Tombola F., Morbiato L., Del Giudice G., et al. The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 108 (2001) 929-937
26. Fujikawa A., Shirasaka D., Yamamoto S., et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 33 (2003) 375-381
27. Yamaoka Y., Kikuchi S., el-Zimaity H.M., et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation and mucosal interleukin 8 production. Gastroenterology 123 (2002) 414-424
28. Logan R.P., Walker M.M., Misiewicz J.J., et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36 (1995) 12-16
29. Peetsalu M., Valle J., Harkonen M., et al. Changes in the histology and function of gastric mucosa and in Helicobacter pylori colonization during a long-term follow-up period after vagotomy in duodenal ulcer patients. Hepatogastroenterology 52 (2005) 785-791
30. El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
31. Hellmig S., Ott S., Rosenstiel P., et al. Genetic variants in matrix metalloproteinase genes are associated with development of gastric ulcer in H. pylori infection. Am J Gastroenterol 101 (2006) 29-35
32. Graham D.Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric ulcer: a Model. Gastroenterology 133 (1997) 1983-1991
33. Van Zanten S.J., Dixon M.F., and Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and Helicobacter ecology. Gastroenterology 116 (1999) 1217-1229
34. Sung J.J., Chung S.C., Ling T.K., et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 332 (1995) 139-142
35. Sung J.J., Leung W.K., Suen R., et al. One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding. Dig Dis Sci 42 (1997) 2524-2528
36. Ciociola A.A., McSorley D.J., Turner K., et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 94 (1999) 1834-1840
37. Nomura A., Stemmermann G.N., Chyou P.H., et al. Helicobacter pylori infection and the risk of duodenal and gastric ulceration. Ann Intern Med 120 (1994) 977-981
38. Laine L., Hopkins R.J., and Girardi L.S. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 93 (1998) 1409-1415
39. Flemstrom G., and Isenberg J.I. Gastroduodenal mucosal alkaline secretion and mucosal protection. News Physiol Sci 16 (2001) 23-28
40. Flemstrom G. Gastric and duodenal mucosal bicarbonate secretion. In: Johnson L.R., Jacobson E.D., Christensen J., et al. (Eds). Physiology of the Gastrointestinal Tract. 3rd ed. (1994), Raven, New York 1285-1309
41. Valle J., Kekki M., Sipponen P., et al. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 31 (1996) 546-550
42. Khulusi S., Mendall M.A., Patel P., et al. Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 37 (1995) 319-324
43. Schubert M.L. Gastric secretion. Curr Opin Gastroenterol 19 (2003) 519-525
44. Peterson W.L., Barnett C.C., Evans Jr. D.J., et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 88 (1993) 2038-2043
45. El-Omar E., Penman I., Dorrian C.A., et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcers. Gut 34 (1993) 1060-1065
46. El-Omar E.M., Penman I.D., Ardill J.E., et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 (1995) 681-691
47. Moss S.F., Legon S., Bishop A.E., et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340 (1992) 930-932
48. Beales I.L., and Calam J. Helicobacter pylori infection and tumour necrosis factor-alpha increase gastrin release from human gastric antral fragments. Eur J Gastroenterol Hepatol 9 (1997) 773-777
49. Beales I., Calam J., Post L., et al. Effect of transforming growth factor alpha and interleukin 8 on somatostatin release from canine fundi D cells. Gastroenterology 112 (1997) 136-143
50. Beales I., Blaser M.J., Srinivasan S., et al. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology 113 (1997) 465-471
51. Graham D.Y. Gastrin-releasing peptic, acid secretion, Helicobacter pylori, and duodenal ulcer: another epiphenomenon?. Gastroenterology 110 (1996) 1325-1326
52. Wyatt J.I., Rathbone B.J., Dixon M.F., et al. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 40 (1987) 841-848
53. Peura D.A. Ulcerogenesis: integrating the roles of Helicobacter pylori and acid secretion in duodenal ulcer. Am J Gastroenterol 92 4 supplement (1997) 8S-13S [discussion 13S-16S]
54. Oi M., and Sakurai Y. The location of duodenal ulcer. Gastroenterology 54 supplement (1968) 741-743
55. Carrick J., Lee A., Hazell S., et al. Campylobacter pylori, duodenal ulcer, and gastric metaplasia: possible role of functional heterotopic tissue in ulcerogenesis. Gut 30 (1989) 790-797
56. Hogan D.L., Rapier R.C., Dreilinger A., et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology 110 (1996) 705-716
57. Isenberg J.I., Selling J.A., Hogan D.L., et al. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med 316 (1987) 374-379
58. Konturek P.C., Ernst H., Konturek S.J., et al. Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori. Gut 40 (1997) 463-469
59. Lu H., Hsu P.I., Graham D.Y., et al. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 128 (2005) 833-848
60. Sheu B.S., Sheu S.M., Yang H.B., et al. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection. Gut 52 (2003) 927-932
61. Ng E.K., Chung S.C., Sung J.J., et al. High prevalence of Helicobacter pylori infection in duodenal ulcer perforations not caused by non-steroidal anti-inflammatory drugs. Br J Surg 83 (1996) 1779-1781
62. Lam Y.H., Lau J.Y., Law B.K., et al. Endoscopic balloon dilation and Helicobacter pylori eradication in the treatment of gastric outlet obstruction. Gastrointest Endosc 46 (1997) 379-380
63. Sung J.J., Chung S.C., Ling T.K., et al. One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori. Am J Gastroenterol 89 (1994) 199-202
64. Hosking S.W., Ling T.K., Chung S.C., et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343 (1994) 508-510
65. Lam Y.H., Lau J.Y., Fung T.M., et al. Endoscopic balloon dilation for benign gastric outlet obstruction with or without Helicobacter pylori infection. Gastrointest Endosc 60 (2004) 229-233
66. Gillen D., and McColl K.E. Gastroduodenal disease, Helicobacter pylori, and genetic polypmorphisms. Clin Gastroenterol Hepatol 3 (2005) 1180-1186
67. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 341 (1999) 548
68. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
69. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
70. Chan F.K., Sung J.J., Chung S.C., et al. Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350 (1997) 975-979
71. Chan F.K., To K.F., Wu J.C., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 (2002) 9-13
72. Labenz J., Blum A.L., Bolten W.W., et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double bind, placebo controlled, clinical trial. Gut 51 (2002) 329-335
73. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomized controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 352 (1998) 1016-1021
74. Vergara M., Catalan M., Gisbert J.P., et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21 (2005) 1411-1418
75. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
76. Chan F.K., Ching J.Y., Suen B.Y., et al. Eradication of H. pylori for the prevention of recurrent ulcer bleeding in high-risk aspirin users: a 4-year prospective cohort study. Gastroenterology 128 (2005) A133
77. Konturek J.W., Dembinski A., Konturek S.J., et al. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 114 (1998) 245-255
78. Kim J.M., Kim J.S., Jung H.C., et al. Upgregulated cyclooxygenase-2 inhibits apoptosis of human gastric epithelial cells infected with Helicobacter pylori. Dig Dis Sci 45 (2000) 2436-2443
79. Futagami S., Hiratusuka T., Wada K., et al. Inhibition of Helicobacter pylori-induced cyclo-oxygenase-2 aggravates NSAID-caused gastric damage in Mongolian gerbils. Aliment Pharmacol Ther 16 (2002) 847-855
80. Scheiman J.M., Greenson J.K., Lee J., et al. Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention. Aliment Pharmacol Ther 17 (2003) 1535-1543
81. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 213 (2002) 1006-1012
82. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
83. El-Serag H.B., and Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 43 (1998) 327-333
84. Vicari J.J., Peek P.M., Goldblum J.R., et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroeosphageal reflux disease. Gastroenterology 115 (1998) 50-57
85. Weston A.P., Badr A.S., Topalovski M., et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenoarcinoma. Am J Gastroenterol 95 (2000) 387-394
86. Vaezi M.F., Falk G.W., Peek R.M., et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 95 (2000) 2206-2211
87. Labenz J., Blum A.L., Bayerdorffer E., et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 (1997) 1442-1447
88. Dent J., El-Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systemic review. Gut 54 (2005) 710-717
89. Wu J.C., Sung J.J., Chan F.K., et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14 (2000) 427-432
90. Muramatsu A., Azuma T., Okuda T., et al. Association between interleukin-1beta-511C/T polymorphism and reflux esophagitis in Japan. J Gastroenterol 40 (2005) 873-877
91. Koike T., Ohara S., Sekine H., et al. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 15 (2001) 813-820
92. Wu J.C., Lai A.C., Wong S.K., et al. Dysfunction of oesophageal motility in Helicobacter pylori-infected patients with reflux oesphagitis. Aliment Pharmacol Ther 15 (2001) 1913-1919
93. Shirota T., Kusano M., Kawamura O., et al. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 34 (1999) 553-559
94. Laine L., and Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 97 (2002) 2992-2997
95. Graham D.Y. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 98 (2003) 1462-1470
96. Ott E.A., Mazzoleni L.E., Edelweiss M.I., et al. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomised, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther 21 (2005) 1231-1239
97. Schwizer W., Thumshirn M., Dent J., et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 357 (2001) 1738-1742
98. Wu J.C., Chan F.K., Ching J.Y., et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 53 (2004) 174-179
99. Moayyedi P., Bardhan C., Young L., et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121 (2001) 1120-1126
100. Harvey R.F., Lane J.A., Murray L.J., et al. Randomized controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ 328 (2004) 1417
101. Pilotto A., Perri F., Leandro G., et al. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elder. A randomised, multicenter, eight-month study. Gerotology 52 (2006) 99-106
102. Talley N.J., Stanghellini V., Heading R.C., et al. Functional gastroduodenal disorders. In: Drossman D.A., Corazziari E., Talley N.H., et al. (Eds). Rome II: The Functional Gastrointestinal Disorders. 2nd ed. (2000), Degnon Associates, McLean 299-350
103. Johnsen R., Bernersen B., Straume B., et al. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ 302 (1991) 749-752
104. Talley N.J., and Hunt R.H. What role does Helicobacter pylori play in dyspepsia and non-ulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 113 6 supplement (1997) S67-S77
105. Mearin F., de Ribot X., Salas A., et al. Does Helicobacter pylori infection increase gastric sensitivity in function dyspepsia?. Gut 37 (1995) 47-51
106. McColl K., Murray L., El-Omar E., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 339 (1998) 1869-1874
107. Blum A.L., Talley N.J., O'Morain C., et al. Lack of effect of treating Helicobacter pylori infection in patients with non-ulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 339 (1998) 1875-1881
108. Talley N.J., Vakil N., Ballard II E.D., et al. Absence of benefit of eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. N Engl J Med 341 (1999) 1106-1111
109. Laine L., Schoenfeld P., and Fennerty M.B. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia. A meta-analysis of randomised controlled trials. Ann Intern Med 134 (2001) 361-369
110. Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori in non-ulcer dyspepsia. Cochrane Database Syst Rev 2 (2006) CD002096
111. Delaney B.C., Innes M.A., Deeks J., et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 3 (2001) CD001961
112. Talley N.J. American Gastroenterological Association Medical Position Statement: Evaluation of Dyspepsia. Gastroenterology 129 (2005) 1753-1755
113. Vutilainen M., Sokka T., Juhola M., et al. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Scand J Gastroenterol 33 (1998) 811-816
114. Kordecki H., Kurowski M., Kosik R., et al. Is Helicobacter pylori infection a risk or protective factor for mucosal lesions development in patients chronically treated with acetylsalicylic acid?. J Physiol Pharmacol 48 supplement 4 (1997) 85-91
115. Santucci L., Fiorucci S., Patoia L., et al. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig Dis Sci 40 (1995) 2074-2080
116. Taha A.S., Angerson W., Nakshabendi I., et al. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs - influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther 7 (1993) 41-45
117. Caselli M., Pazzi P., Lacorte R., et al. Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 44 (1989) 101-104
118. Shallcross T.M., Rathbone B.J., Wyatt J.I., et al. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 4 (1990) 515-522
119. Mizokami Y., Tamura K., Fukuda Y., et al. Non-steroidal anti-inflammatory drugs associated with gastroduodenal injury and Helicobacter pylori. Eur J Gastroenterol Hepatol 6 supplement 1 (1994) S109-S112
120. Taha A.S., Nakshabendi I., Lee F.D., et al. Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration. J Clin Pathol 45 (1992) 135-139
121. Kim J.G., and Graham D.Y. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 89 (1994) 203-207
122. Pilotto A., Franceschi M., Leandro G., et al. The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. Eur J Gastroenterol Hepatol 9 (1997) 951-956
123. Bianchi Porro G., Parente F., Imbesi V., et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut 39 (1996) 22-26
124. Li E.K., Sung J.J., Suen R., et al. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. Scand J Rheumatol 25 (1996) 42-46
125. Graham D.Y., Lidsky M.D., Cox A.M., et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 100 (1991) 1653-1657
126. Loeb D.S., Talley N.J., Ahlquist D.A., et al. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 102 (1992) 1899-1905
127. Vcev A., Ivandic A., Vceva A., et al. Infection with Helicobacter pylori and long-term use of non-steroidal antiinflammatory drugs. Acta Med Croatica 52 (1998) 27-31
128. Upadhyay R., Howatson A., McKinlay A., et al. Campylobacter pylori associated gastritis in patients with rheumatoid arthritis taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol 27 (1988) 113-116
129. Chan F.K., and Leung W.K. Peptic-ulcer disease. Lancet 360 (2002) 933-941